Clinical trials: Untreated
Acute Myeloid Leukemia (AML)
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations.
- Trial name
- NCT07007312
- Testing
- Ziftomenib, Venetoclax, Azacitidine (AZA)
- Where
- 136 sites in United States, Australia and 15 more
- Volunteers
- 1,300 people
- Sponsor
- Kura Oncology, Inc.
Colorectal Cancer
A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer
Bevacizumab has recently been shown to improve survival when combined with chemotherapy in patients with previously untreated metastatic colorectal cancer.
- Trial name
- NCT00483834
- Testing
- Bevacizumab, Irinotecan, Capecitabine
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University Health Network, Toronto
Pancreas Cancer, Pancreatic Carcinoma
Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC
The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.
- Conditions
- Pancreas Cancer, Pancreatic Carcinoma, Pancreas Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- FORTIFIDE (NCT06592664)
- Testing
- certepetide, nab-paclitaxel, gemcitabine
- Sponsor
- Lisata Therapeutics, Inc.
Leukemia
Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as clofarabine and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00814164
- Testing
- clofarabine, daunorubicin hydrochloride, cytogenetic analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Roswell Park Cancer Institute
Gastric Cancer, Peritoneal Metastases
Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
To evaluate the efficacy and safety of Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion as First-line Treatment for advanced gastric/gastroesophageal junction (GC/GEJ) adenocarcinoma…
- Conditions
- Gastric Cancer, Peritoneal Metastases, Ascites, Malignant
- Trial name
- NCT06046963
- Testing
- Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion, Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhejiang Cancer Hospital
Chronic Lymphocytic Leukemia
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
The purpose of this study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated chronic lymphocytic leukemia (CLL).
- Trial name
- NCT06637501
- Testing
- Sonrotoclax, Zanubrutinib
- Where
- 32 sites in United States, Brazil and 4 more
- Volunteers
- 94 people
- Sponsor
- BeOne Medicines
Large B-Cell Lymphoma (LBCL)
AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL
This is a prospective, open-label, multicenter, randomized controlled study in participants with previously untreated large B-cell lymphoma.
- Trial name
- GUIDANCE-10 (NCT07594899)
- Testing
- Polatuzumab Vedotin, rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Ruijin Hospital
Pancreatic Cancer, Biliary Cancer
A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers
Multi-agent chemotherapy has value for patients with advanced pancreatic-biliary cancers leading to responses in a substantial minority and increasing survival.
- Trial name
- NCT01661114
- Testing
- Gemcitabine, 5-FU, Cisplatin
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Michigan Rogel Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill metastatic cancer cells. Interferon alfa may interfere with the growth of the cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00002504
- Testing
- aldesleukin, recombinant interferon alfa
- Where
- 5 sites in United States
- Sponsor
- Hoag Memorial Hospital Presbyterian
Non Small Cell Lung Cancer, Cancer
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression
Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers.
- Trial name
- NCT04274907
- Testing
- Venetoclax, Pembrolizumab
- Where
- 39 sites in United States
- Volunteers
- 2 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7)
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia
This randomized phase II trial is studying the side effects and how well giving tipifarnib together with etoposide works in treating older patients with newly diagnosed, previously untreated acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00602771
- Testing
- tipifarnib, etoposide
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, T-Cell, Peripheral
Brentuximab Vedotin in Combination With CHEP in Patient With PTCL
A Phase II Open Label Study of Brentuximab Vedotin in Combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas (PTCL)
- Trial name
- NCT05006664
- Testing
- Adcetris 50 MG Injection, Endoxan, Doxorubicin
- Where
- 7 sites in Czechia
- Volunteers
- 33 people
- Sponsor
- Czech Lymphoma Study Group
Initial MZL, Untreated MZL
Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL
This is a multi-center, prospective cohort study. The main purpose of study is to evaluate the efficacy and safety of Orelabrutinib combined with Zuberitamab in the initial treatment of MZL Main efficacy indicators Complete…
- Conditions
- Initial MZL, Untreated MZL, BTKi, CD20
- Trial name
- ZOOM (NCT06985472)
- Testing
- ZO
- Where
- 2 sites in China
- Volunteers
- 33 people
- Sponsor
- Li Zhiming
Multiple Myeloma
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Bortezomib (Velcade) has just recently been approved by the FDA for the treatment of multiple myeloma in patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy.
- Trial name
- NCT00153920
- Testing
- bortezomib
- Where
- 6 sites in United States
- Volunteers
- 66 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma, B-Cell, Follicular Lymphoma
A Phase I/II Trial of VR-CHOP in Lymphoma Patients
This is an open-label (doctors and patients know which drug will be given), single center, phase 1/2 clinical trial. The primary objective is to determine whether VR-CHOP provides benefit to patients with previously untreated…
- Trial name
- NCT00634179
- Testing
- Bortezomib, Rituximab, Doxorubicin
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Emory University
Biliary Tract Cancer, HER2 Gene Mutation
Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer
This is a multicenter, single arm, prospective, open-label phase II trial investigating the clinical activity triplet regimen consisting of a combination of chemotherapy (gemcitabine/cisplatin) + trastuzumab + pembrolizumab as…
- Conditions
- Biliary Tract Cancer, HER2 Gene Mutation, HER2
- Trial name
- TRAP-BTC (NCT06178445)
- Testing
- SOC plus trastuzumab and pembrolizumab
- Where
- 8 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Leukemia, Lymphoma
Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00026351
- Testing
- rituximab, pentostatin
- Where
- 5 sites in United States
- Sponsor
- Pharmatech Oncology
Sarcoma
Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma
RATIONALE: Drugs used in chemotherapy, such as vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00245089
- Testing
- dactinomycin, cyclophosphamide, vincristine sulfate
- Where
- 48 sites in Japan
- Volunteers
- 41 people
- Sponsor
- Japan Rhabdomyosarcoma Study Group
Leukemia, Lymphocytic, Chronic
Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL
A prospective, open-label, multicentre phase-II trial of ibrutinib plus venetoclax plus obinutuzumab in physically fit (CIRS ≤ 6 \& normal creatinine clearance) and unfit (CIRS > 6 \& creatinine clearance ≥ 50 ml/min) patients…
- Trial name
- CLL2-GiVe (NCT02758665)
- Testing
- ibrutinib, obinutuzumab, venetoclax
- Where
- 11 sites in Germany
- Volunteers
- 41 people
- Sponsor
- University of Ulm
Untreated Follicular Lymphoma
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3…
- Trial name
- NCT06549595
- Testing
- Surovatamig, R-CHOP, R-CVP
- Where
- 244 sites in United States, Australia and 23 more
- Volunteers
- 1,018 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.